Time trend of respiratory viruses before and during the COVID-19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022
© 2023 World Health Organization; licensed by John Wiley & Sons Ltd. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd..
Introduction: Severe acute respiratory illness (SARI) is a potentially lethal condition, necessitating thorough medical care. COVID-19 underscored the SARI threat, but other high-risk pathogens require monitoring alongside SARS-CoV-2. Oman instituted a comprehensive testing system to gauge the prevalence of these pathogens between 2017 and 2021, aiding resource allocation and public health responses to potential respiratory pathogen outbreaks.
Methods: Samples from SARI cases admitted to ICU were tested for pathogens using the Fast-Track Diagnostic (FTD) molecular assay, a respiratory virus panel (RVP) that tests for 21 pathogens, including 20 viruses, by qPCR.
Results: Between 2017 and 2022, ~30 000 samples were analysed using the RVP panel. Among SARI patients, 8%-42% tested positive for respiratory pathogens, with 4% showing multiple infectious agents, especially in children under 10. A drop in positivity during 2020-2021 can be attributed to SARS-CoV-2 control measures, followed by a rebound in infections in early 2022.
Discussion: The COVID-19 pandemic heightened awareness of respiratory pathogens' spread without adequate control measures. Influenza A/B, human rhinoviruses and respiratory syncytial virus constituted over 50% of severe acute respiratory illness cases in Oman over the past 5 years. During the pandemic, the incidence of these infections significantly declined, demonstrating the efficacy of COVID-19 prevention measures in reducing spread of other pathogens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 17(2023), 12 vom: 15. Dez., Seite e13233 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Kindi, Hanan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID‐19 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 10.02.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.13233 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365893447 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365893447 | ||
| 003 | DE-627 | ||
| 005 | 20240210232956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.13233 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM365893447 | ||
| 035 | |a (NLM)38098648 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Kindi, Hanan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Time trend of respiratory viruses before and during the COVID-19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 World Health Organization; licensed by John Wiley & Sons Ltd. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd. | ||
| 520 | |a Introduction: Severe acute respiratory illness (SARI) is a potentially lethal condition, necessitating thorough medical care. COVID-19 underscored the SARI threat, but other high-risk pathogens require monitoring alongside SARS-CoV-2. Oman instituted a comprehensive testing system to gauge the prevalence of these pathogens between 2017 and 2021, aiding resource allocation and public health responses to potential respiratory pathogen outbreaks | ||
| 520 | |a Methods: Samples from SARI cases admitted to ICU were tested for pathogens using the Fast-Track Diagnostic (FTD) molecular assay, a respiratory virus panel (RVP) that tests for 21 pathogens, including 20 viruses, by qPCR | ||
| 520 | |a Results: Between 2017 and 2022, ~30 000 samples were analysed using the RVP panel. Among SARI patients, 8%-42% tested positive for respiratory pathogens, with 4% showing multiple infectious agents, especially in children under 10. A drop in positivity during 2020-2021 can be attributed to SARS-CoV-2 control measures, followed by a rebound in infections in early 2022 | ||
| 520 | |a Discussion: The COVID-19 pandemic heightened awareness of respiratory pathogens' spread without adequate control measures. Influenza A/B, human rhinoviruses and respiratory syncytial virus constituted over 50% of severe acute respiratory illness cases in Oman over the past 5 years. During the pandemic, the incidence of these infections significantly declined, demonstrating the efficacy of COVID-19 prevention measures in reducing spread of other pathogens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID‐19 | |
| 650 | 4 | |a SARI/ILI | |
| 650 | 4 | |a laboratory | |
| 650 | 4 | |a respiratory | |
| 650 | 4 | |a surveillance | |
| 700 | 1 | |a Meredith, Luke William |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Jardani, Amina |e verfasserin |4 aut | |
| 700 | 1 | |a Sajina, Fathima |e verfasserin |4 aut | |
| 700 | 1 | |a Al Shukri, Intisar |e verfasserin |4 aut | |
| 700 | 1 | |a Al Haj, Rehan |e verfasserin |4 aut | |
| 700 | 1 | |a Alyaquobi, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Al Wahaibi, Adil |e verfasserin |4 aut | |
| 700 | 1 | |a Al Maani, Amal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 17(2023), 12 vom: 15. Dez., Seite e13233 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:12 |g day:15 |g month:12 |g pages:e13233 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.13233 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 12 |b 15 |c 12 |h e13233 | ||